Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) was the target of a large growth in short interest in August. As of August 15th, there was short interest totalling 1,970,000 shares, a growth of 5.9% from the July 31st total of 1,860,000 shares. Currently, 4.3% of the company’s stock are sold short. Based on an average daily trading volume, of 1,670,000 shares, the days-to-cover ratio is presently 1.2 days.
Amylyx Pharmaceuticals Stock Up 4.7 %
Shares of NASDAQ AMLX traded up $0.10 during mid-day trading on Monday, reaching $2.22. 414,100 shares of the company were exchanged, compared to its average volume of 2,185,571. The stock has a market cap of $150.97 million, a price-to-earnings ratio of -2.07 and a beta of -0.63. Amylyx Pharmaceuticals has a 1 year low of $1.58 and a 1 year high of $22.03. The firm has a 50-day moving average of $2.01 and a 200 day moving average of $3.86.
Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.35). The company had revenue of ($1.02) million for the quarter, compared to analysts’ expectations of $18.83 million. Amylyx Pharmaceuticals had a negative return on equity of 15.51% and a negative net margin of 17.86%. During the same quarter last year, the company earned $0.31 earnings per share. On average, equities analysts forecast that Amylyx Pharmaceuticals will post -2.27 earnings per share for the current year.
Institutional Investors Weigh In On Amylyx Pharmaceuticals
Wall Street Analysts Forecast Growth
A number of equities analysts have recently issued reports on AMLX shares. HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of Amylyx Pharmaceuticals in a research report on Wednesday, July 10th. The Goldman Sachs Group increased their price target on Amylyx Pharmaceuticals from $3.00 to $4.00 and gave the stock a “neutral” rating in a research report on Friday, July 12th. Finally, Mizuho dropped their price target on Amylyx Pharmaceuticals from $4.00 to $3.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 14th. Six research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $17.60.
View Our Latest Stock Analysis on AMLX
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.
Further Reading
- Five stocks we like better than Amylyx Pharmaceuticals
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Autodesk Stock: Analysts’ Top AI Pick You Shouldn’t Overlook
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Hidden Opportunities in Li Auto’s Tough Quarter You Can’t Miss
- What is a Low P/E Ratio and What Does it Tell Investors?
- Don’t Overlook Campbell Soup: Here’s What Could Drive Its Stock
Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.